Insider Trading Alert - KMI, BMRN And ACAS Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Feb. 24, 2014, 153 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $614.00 to $8,867,579,754,879.72.

Highlighted Stocks Traded by Insiders:

Kinder Morgan (KMI) - FREE Research Report

Kinder Richard D who is Chairman and CEO at Kinder Morgan bought 199,165 shares at $32.09 on Feb. 24, 2014. Following this transaction, the Chairman and CEO owned 231.9 million shares meaning that the stake was reduced by 0.09% with the 199,165-share transaction.

Sanders Dax who is Vice President, Corporate Dev. at Kinder Morgan bought 1,000 shares at $32.35 on Feb. 24, 2014. Following this transaction, the Vice President, Corporate Dev. owned 266,499 shares meaning that the stake was reduced by 0.38% with the 1,000-share transaction.

The shares most recently traded at $32.31, down $0.04, or 0.12% since the insider transaction. Historical insider transactions for Kinder Morgan go as follows:

  • 4-Week # shares bought: 20,000
  • 12-Week # shares bought: 849,309
  • 24-Week # shares bought: 849,309

The average volume for Kinder Morgan has been 6.2 million shares per day over the past 30 days. Kinder Morgan has a market cap of $34.2 billion and is part of the basic materials sector and energy industry. Shares are down 10.83% year-to-date as of the close of trading on Monday.

Kinder Morgan, Inc. owns and operates energy transportation and storage assets in the United States and Canada. The company operates in six segments: Natural Gas Pipelines, Products Pipelines KMP, CO2 KMP, Terminals KMP, Kinder Morgan Canada KMP, and Other. The stock currently has a dividend yield of 4.97%. The company has a P/E ratio of 28.7. Currently there are 6 analysts that rate Kinder Morgan a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on KMI - FREE

TheStreet Quant Ratings rates Kinder Morgan as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, compelling growth in net income, growth in earnings per share, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Kinder Morgan Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Biomarin Pharmaceutical (BMRN) - FREE Research Report

Bienaime Jean Jacques who is Chief Executive Officer at Biomarin Pharmaceutical sold 8,000 shares at $80.00 on Feb. 24, 2014. Following this transaction, the Chief Executive Officer owned 46,740 shares meaning that the stake was reduced by 14.61% with the 8,000-share transaction.

The shares most recently traded at $81.50, up $1.50, or 1.84% since the insider transaction. Historical insider transactions for Biomarin Pharmaceutical go as follows:

  • 4-Week # shares sold: 916
  • 12-Week # shares sold: 3,816
  • 24-Week # shares sold: 3,915

The average volume for Biomarin Pharmaceutical has been 1.1 million shares per day over the past 30 days. Biomarin Pharmaceutical has a market cap of $11.6 billion and is part of the health care sector and drugs industry. Shares are up 16.66% year-to-date as of the close of trading on Monday.

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Currently there are 11 analysts that rate Biomarin Pharmaceutical a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BMRN - FREE

TheStreet Quant Ratings rates Biomarin Pharmaceutical as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity. Get the full Biomarin Pharmaceutical Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

American Capital (ACAS) - FREE Research Report

Flax Samuel Allan who is EVP, GC and Secretary at American Capital sold 866 shares at $15.79 on Feb. 24, 2014. Following this transaction, the EVP, GC and Secretary owned 413,419 shares meaning that the stake was reduced by 0.21% with the 866-share transaction.

The shares most recently traded at $15.51, down $0.28, or 1.81% since the insider transaction. Historical insider transactions for American Capital go as follows:

  • 4-Week # shares sold: 131,508
  • 12-Week # shares bought: 15,000
  • 12-Week # shares sold: 163,517
  • 24-Week # shares bought: 15,000
  • 24-Week # shares sold: 244,739

The average volume for American Capital has been 2.6 million shares per day over the past 30 days. American Capital has a market cap of $4.5 billion and is part of the financial sector and financial services industry. Shares are up 0.77% year-to-date as of the close of trading on Monday.

American Capital, Ltd. is a private equity and venture capital firm specializing in management and employee buyouts, leveraged finance, mezzanine, acquisition, recapitalization, middle market, and growth capital investments. The company has a P/E ratio of 30.9. Currently there are 2 analysts that rate American Capital a buy, 1 analyst rates it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ACAS - FREE

TheStreet Quant Ratings rates American Capital as a hold. The company's strengths can be seen in multiple areas, such as its expanding profit margins and increase in stock price during the past year. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and feeble growth in the company's earnings per share. Get the full American Capital Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

China Slashes Auto Import Tariffs as Trump's Trade Push Gets Big Early Win

China Slashes Auto Import Tariffs as Trump's Trade Push Gets Big Early Win

Global Stocks Ease as Investors Focus on Dollar, Oil, Italy After US-China Truce

Global Stocks Ease as Investors Focus on Dollar, Oil, Italy After US-China Truce

Replay: Jim Cramer on Tariffs, the Market Rally, Caterpillar and Micron

Replay: Jim Cramer on Tariffs, the Market Rally, Caterpillar and Micron

Video: When Planning for Retirement, Don't Underestimate Your Life Span

Video: When Planning for Retirement, Don't Underestimate Your Life Span

Video: Here's What May Come Next for Theranos Founder and CEO Elizabeth Holmes

Video: Here's What May Come Next for Theranos Founder and CEO Elizabeth Holmes